Compare OPBK & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPBK | PEPG |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.9M | 207.1M |
| IPO Year | 2018 | 2022 |
| Metric | OPBK | PEPG |
|---|---|---|
| Price | $15.36 | $2.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $16.50 | $11.17 |
| AVG Volume (30 Days) | 38.7K | ★ 693.1K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | 23.74 | ★ 25.61 |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $3,204,000.00 | N/A |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | $11.60 | N/A |
| P/E Ratio | $14.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.41 | $1.31 |
| 52 Week High | $16.83 | $7.80 |
| Indicator | OPBK | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 53.69 |
| Support Level | $13.57 | $1.50 |
| Resistance Level | $15.61 | $3.14 |
| Average True Range (ATR) | 0.27 | 0.22 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 43.18 | 13.64 |
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.